GLP-1

English

Noun

GLP-1 (countable and uncountable, plural GLP-1s)

(biochemistry) Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone).
(informal, countable) Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss.
Hyponym: semaglutide
- 2023 October 9, Tressie McMillan Cottom, “Ozempic Can’t Fix What Our Culture Has Broken”, in The New York Times‎^[1], →ISSN:
  If GLP-1 drugs only treated diabetes and did not promote weight loss, they would still be medically groundbreaking.
- 2024 February 29, Edward Helmore, “Oprah Winfrey announces she is stepping down from WeightWatchers”, in The Guardian‎^[2], →ISSN:
  An apparent conflict between WeightWatchers, which promotes a non-medical, points-based approach to food intake, and the talkshow host came in December when she told People magazine that she integrated GLP-1 drugs, brands that include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, into her existing “holistic approach” of “regular exercise and other lifestyle tweaks”.
- 2025 April 29, Tammy LaGorce, “How Ozempic Is Shaping Weddings”, in The New York Times‎^[3], →ISSN:
  Some brides say explicitly that they are using GLP-1s, while for others, Ms. Yang, who said she uses Mounjaro herself, has her suspicions.
- 2025 May 10, “WeightWatchers blames diet drugs and social media for Chapter 11 bankruptcy”, in FT Weekend, page 13:
  Its lawyers said it could no longer service a $1.6bn debt load because of an “evolution in consumer preferences and the rapid rise of GLP-1s”, and it was seeking an aggregate valuation of $700mn.
- 2025 May 15, Jennifer Weiner, “WeightWatchers Got One Thing Very Right”, in The New York Times‎^[4], →ISSN:
  Those days are gone. WeightWatchers and its commercial diet program peers have struggled to maintain market share in the era of GLP-1s, the class of drugs that includes Ozempic, Wegovy and Mounjaro, which give users a much higher chance of success.